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obular capillary hemangiomas, also known as
pyogenic granulomas, are common, benign,
vascular proliferations of the cutaneous or
mucous surfaces that grow rapidly and are prone to
ulceration and bleeding.1,2 Recurrence of lobular
capillary hemangiomas in the same location after
treatment is commonwith rates ranging from 3.7% to
43.5%.3 Well-known causes of lobular capillary
hemangiomas are trauma, infection, medication,
chronic irritation, viral oncogenes, increased levels
of female sex hormones, and microscopic arteriove-
nous anastomoses.1 Patients commonly seek treat-
ment because of associated pain or discomfort from
ulceration, bleeding, or both. Surgical excision and
cryotherapy show best therapeutic outcomes for
lobular capillary hemangiomas, although electro-
dessication, shave excision, imiquimod cream,
topical timolol, and sclerotherapy are also used.3,4
We report a case of frequent lobular capillary
hemangioma development in the setting of von
Hippel-Lindau syndrome (VHL) and neurofibroma-
tosis type 1 (NF1), requiring multiple treatment
modalities.
CASE REPORT
A 34-year-old man with a history of VHL and NF1
was referred to dermatology for evaluation and
management of multiple bleeding papules. The
papules were tender, and the bleeding caused his
pillowcases to be soaked in blood. He reported
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successful and did not cause satellitosis. New pap-
ules would appear gradually over years, and at the
time of the visit, 6 papules were bothersome because
of intermittent bleeding.
The patient was given the diagnosis of NF1 based
on clinical findings that were first noted in childhood
including multiple cafe au lait macules, axillary
freckling, and Lisch nodules. VHL was suspected
after magnetic resonance imaging showed heman-
gioblastoma of the left cerebellum during evaluation
of sensorineural hearing loss. VHL was subsequently
confirmed by mutation analysis (P81S mutation).
Central nervous system hemangioblastoma is the
most common tumor in VHL and was present in the
patient. He did not have any additional tumors or
cysts in the central nervous system or visceral organs
that are common in VHL, which include retinal
hemangioblastomas, renal cell carcinoma and cysts,
pheochromocytomas, and pancreatic tumors and
cysts.5 The patient did not have family history of
NF1 or VHL. Medications included dextroamphet-
amine for attention deficit disorder.
On physical examination, the lesions of concern
were exophytic, red, vascular papules located on the
right jawline, front of the right shoulder, left lower
aspect of the back, and right lower aspect of the
back, consistent with lobular capillary hemangiomas
(Fig 1). These were painful with slight pressure.
Several other similar, although smaller, papules were
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Fig 1. Two vascular papules on the right jawline and front
of the right shoulder. Asymptomatic ill-defined soft nodule
on the right upper lip.
Fig 2. Multiple cafe au lait macules, axillary freckling, and
neurofibromas on the torso and abdomen.
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defined, ovoid, light-brown macules. Involving the
chest, abdomen, and back were multiple discrete 4-
to 8-mm subcutaneous rubbery-soft nodules (Fig 2).
Axillary freckling was noted on both axilla and the
groin. The patient returned to the dermatology clinic
4 months later with new growing and bleeding
vascular papules in new locations; they were similar
to those removed at the initial visit and consistent
with lobular capillary hemangiomas.
There are many options for treatment of lobular
capillary hemangiomas. In our patient, these lesions
were treated by shave excision with electrodessica-
tion and samples were sent for histologic evaluation
(Fig 3). At the follow-up visit 4 months later, 5
additional lesions were destroyed with the same
approach. Neither recurrence nor satellitosis was
noted at sites of prior treatment.Fig 3. Proliferating capillaries grouped into lobules by
dense fibrous bands, clutched by an epithelial collarette.
(Hematoxylin-eosin stain; original magnification: 320.)DISCUSSION
NF1 and VHL are both autosomal dominant
syndromes caused bymutations of tumor suppressor
genes with prevalences of 1:3,000 and 1:36,000
respectively.5,6 The presence of 2 independent
genetic syndromes in the same individual is
extremely rare, and this case represents a chance
event rate of 1 in 108,000,000 (based on the com-
bined prevalence of VHL 1:36,000 and NF1
1:3000).5,6 NF1 occurs as a result of mutation of the
NF1 tumor suppressor gene (chromosome 17), lead-
ing to neurofibromas, cafe au lait macules, central
nervous system gliomas, and bony abnormalities.6
VHL occurs as a result of amutation in the VHL tumor
suppressor gene (chromosome 3), which leads to
unregulated growth of vascular tumors in multipletissues. Common VHL tumors include hemangio-
blastomas of the retina, brain, and viscera along with
renal cell carcinoma and pheochromocytoma.5,7 In
VHL, angiogenesis is likely the result of increased
levels of glucose transporter 1, vascular endothelial
growth factor, and platelet-derived growth factor.5
Unlike in NF1, VHL does not exhibit cutaneous
Fig 4. Potential pathway for recurrent lobular capillary
hemangiomas (LCH ) in this patient. There are several
well-known causes for lobular capillary hemangiomas.1 In
the setting of von Hippel-Lindau syndrome (VHL), there is
increased vascular endothelial growth factor (VEGF ),5
which we hypothesize predisposes our patient to more
frequent development of lobular capillary hemangiomas




370 Haitz et alfindings.8 Interestingly, lobular capillary hemangi-
omas have not been described in association with
either NF1 or VHL.
This patient shows an uncommon growth pattern
of lobular capillary hemangiomas with numerous
lesions in new locations that require periodic treat-
ment for symptom relief rather than the typical
recurrent lobular capillary hemangioma in the
same location. Based on known predisposing factors
of lobular capillary hemangiomas and based on the
pathophysiology of this patient’s genetic diseases,
we hypothesize that increased vascular endothelial
growth factor in addition to minor trauma contrib-
uted to this presentation (Fig 4).We present a case of a patient with VHL and NF1,
and very frequent development of lobular capillary
hemangiomas. We hypothesize that this phenome-
non is related to the angiogenesis pathways induced
by VHL. Further studies are needed to examine a
connection between VHL and/or NF1 and lobular
capillary hemangiomas.
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